City Therapeutics
PrivateLast Round
Series B
Jun 8, 2026
Total Funding Raised
$264.5M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
City Therapeutics is a biotechnology company that develops next-generation RNA interference (RNAi) therapeutics designed to silence disease-causing genes by targeting and degrading messenger RNA.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
City Therapeutics Comparables
Compare City Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sanegene Bio | 84% | |
| Atalanta Therapeutics | 79% | |
| Suzhou Ribo Life Science Co., Ltd. | 78% |
City Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 8, 2026 | ||||
| Convertible Debt | May 27, 2025 | ||||
| Series A | Oct 8, 2024 |
City Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| ARCH Venture Partners | Series B, Series A |
| Fidelity Management & Research Company | Series B, Series A |
| Invus Opportunities | Series B |
| ARCH Venture Partners | Series A |
| Viking Global Investors | Series B |
| AN Venture Partners | Series B, Series A |
| Casdin Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 75% MoM.
- Jun 8, 2026
$100M round led by Viking Global Investors and Sofinnova Investments.
Recent news
Latest coverage and updates
- hiresAug 11, 2026
Citytx hired Mary Beth DeLena as Chief Legal Officer on Aug 11th '26.
- hiresAug 11, 2026
Citytx hired Keith Regnante as Chief Financial Officer on Aug 11th '26.
City Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about City Therapeutics's valuation, stock price, and market status.
Is City Therapeutics a public or private company?
City Therapeutics is a private company.
What is the current stock price of City Therapeutics?
City Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is City Therapeutics worth (valuation)?
Valuation information for City Therapeutics is not publicly available.
Can I buy City Therapeutics stock?
City Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was City Therapeutics's last funding round?
City Therapeutics's most recent funding round was Series B on June 8, 2026.
Who are the main investors in City Therapeutics?
Key investors in City Therapeutics include ARCH Venture Partners, Viking Global Investors, Sofinnova Investments.
Will City Therapeutics IPO soon?
No public IPO plans have been announced for City Therapeutics.
How can I track City Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor City Therapeutics's secondary market activity and sign up for updates.